Immunocore to present at upcoming investor conferences
Immunocore (NASDAQ: IMCR), a commercial-stage biotechnology company, has announced its participation in four major investor conferences in September 2025. The company will participate in the Cantor Global Healthcare Conference (Sept 5), H.C. Wainwright Global Investment Conference (Sept 8), Baird Global Healthcare Conference (Sept 9), and Morgan Stanley Global Healthcare Conference (Sept 10).
Immunocore specializes in developing novel TCR bispecific immunotherapies (ImmTAX) for cancer, autoimmune, and infectious diseases. Their flagship product, KIMMTRAK, is approved in multiple regions for treating HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Immunocore (NASDAQ: IMCR), una società biotecnologica in fase commerciale, ha annunciato la partecipazione a quattro importanti conferenze per investitori a settembre 2025. L'azienda sarà presente al Cantor Global Healthcare Conference (5 settembre), al H.C. Wainwright Global Investment Conference (8 settembre), al Baird Global Healthcare Conference (9 settembre) e al Morgan Stanley Global Healthcare Conference (10 settembre).
Immunocore è specializzata nello sviluppo di nuove immunoterapie bispecifiche TCR (ImmTAX) per cancro, malattie autoimmuni e infettive. Il loro prodotto di punta, KIMMTRAK, è approvato in varie aree per il trattamento di pazienti adulti HLA-A*02:01 positivi con melanoma uveale non resecabile o metastatico.
Immunocore (NASDAQ: IMCR), una biotecnológica en fase comercial, ha anunciado su participación en cuatro importantes conferencias de inversores en septiembre de 2025. La compañía asistirá al Cantor Global Healthcare Conference (5 de septiembre), al H.C. Wainwright Global Investment Conference (8 de septiembre), al Baird Global Healthcare Conference (9 de septiembre) y al Morgan Stanley Global Healthcare Conference (10 de septiembre).
Immunocore se especializa en el desarrollo de nuevas inmunoterapias TCR bispecíficas (ImmTAX) para cáncer, enfermedades autoinmunes e infecciosas. Su producto principal, KIMMTRAK, está aprobado en varias regiones para el tratamiento de pacientes adultos HLA-A*02:01 positivos con melanoma uveal irresecable o metastásico.
Immunocore (NASDAQ: IMCR)는 상업 단계의 바이오테크 기업으로 2025년 9월 주요 투자자 컨퍼런스 네 곳에 참가한다고 발표했습니다. 회사는 Cantor Global Healthcare Conference(9월 5일), H.C. Wainwright Global Investment Conference(9월 8일), Baird Global Healthcare Conference(9월 9일) 및 Morgan Stanley Global Healthcare Conference(9월 10일)에 참석할 예정입니다.
Immunocore는 암, 자가면역질환 및 감염질환을 겨냥한 새로운 TCR 이중특이성 면역치료제(ImmTAX) 개발을 전문으로 합니다. 주력 제품인 KIMMTRAK은 절제 불가능하거나 전이된 포도막 흑색종(HLA-A*02:01 양성) 성인 환자 치료를 위해 여러 지역에서 승인받았습니다.
Immunocore (NASDAQ: IMCR), une société biotechnologique en phase commerciale, a annoncé sa participation à quatre grandes conférences investisseurs en septembre 2025. La société prendra part au Cantor Global Healthcare Conference (5 septembre), au H.C. Wainwright Global Investment Conference (8 septembre), au Baird Global Healthcare Conference (9 septembre) et au Morgan Stanley Global Healthcare Conference (10 septembre).
Immunocore se spécialise dans le développement de nouvelles immunothérapies bispécifiques TCR (ImmTAX) pour le cancer, les maladies auto-immunes et les maladies infectieuses. Leur produit phare, KIMMTRAK, est approuvé dans plusieurs régions pour le traitement des patients adultes HLA-A*02:01 positifs atteints de mélanome uvéal non résécable ou métastatique.
Immunocore (NASDAQ: IMCR), ein Biotechnologieunternehmen in der kommerziellen Phase, hat seine Teilnahme an vier wichtigen Investorenkonferenzen im September 2025 angekündigt. Das Unternehmen wird am Cantor Global Healthcare Conference (5. Sept.), am H.C. Wainwright Global Investment Conference (8. Sept.), am Baird Global Healthcare Conference (9. Sept.) und am Morgan Stanley Global Healthcare Conference (10. Sept.) teilnehmen.
Immunocore spezialisiert sich auf die Entwicklung neuartiger TCR-bispezifischer Immuntherapien (ImmTAX) für Krebs, Autoimmun- und Infektionskrankheiten. Ihr Flaggschiffprodukt, KIMMTRAK, ist in mehreren Regionen zur Behandlung von HLA-A*02:01-positiven erwachsenen Patientinnen und Patienten mit nicht resezierbarem oder metastasiertem Uveamelanom zugelassen.
- None.
- None.
Immunocore to present at upcoming investor conferences
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, September 3, 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in September.
Cantor Global Healthcare Conference
Fireside Chat: Friday, September 5, 2025, at 8:35 a.m. EDT
H.C. Wainwright 27th Annual Global Investment Conference
1x1 and small group meetings: Monday, September 8, 2025
Baird 2025 Global Healthcare Conference
Fireside Chat: Tuesday, September 9, 2025, at 10:15 a.m. EDT
Morgan Stanley 23rd Annual Global Healthcare Conference
Fireside Chat: Wednesday, September 10, 2025, at 1:50 p.m. EDT
Where relevant, the presentations will be webcast live and can be accessed by visiting ‘Events & Presentations’, under ‘Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay of the presentations will be made available for a limited time.
About Immunocore
Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including numerous active clinical and pre-clinical programs in oncology, infectious diseases, and autoimmune diseases. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.
Contact Information
Immunocore
Sébastien Desprez, VP Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow Immunocore on LinkedIn: @Immunocore
Investor Relations
Clayton Robertson / Morgan Warenius
T: +1 (215) 384-4781
E: ir@immunocore.com
FAQ
When is Immunocore (IMCR) presenting at the Morgan Stanley Healthcare Conference 2025?
What is Immunocore's (IMCR) main approved product?
How can investors access Immunocore's (IMCR) conference presentations?
What type of technology does Immunocore (IMCR) develop?
